← Back to Search

Phosphorus Binder

Lanthanum Carbonate (Fosrenol) for Metabolic Bone Diseases

N/A
Waitlist Available
Led By Stuart M Sprague, DO
Research Sponsored by NorthShore University HealthSystem
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and non-pregnant females ages 18 years of age or older
Estimated GFR between 15-60 ml/min/1.73m
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 60 days
Awards & highlights

Study Summary

The aim of the study is to assess the effects of the drug lanthanum carbonate (a phosphorus binder drug) on c-terminal and on FGF23 levels in patients with Chronic Kidney Disease (CKD). Targeting FGF23 measurement in CKD patients may impact both the progression of kidney disease and patient mortality.

Eligible Conditions
  • Metabolic Bone Diseases

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 60 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 60 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Fibroblast Growth Factor (FGF) 23 Mean Change From Baseline
Secondary outcome measures
1,25 Dihydroxyvitamin D 3 Mean Change From Baseline
24 Hour Urine Phosphate Mean Change From Baseline
25 Hydroxyvitamin D Mean Change From Baseline
+5 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Lanthanum Carbonate (Fosrenol)Active Control1 Intervention
Subjects will receive the study drug Lanthanum Carbonate ( Fosrenol)
Group II: PlaceboPlacebo Group1 Intervention
Subject will receive placebo

Find a Location

Who is running the clinical trial?

ShireIndustry Sponsor
456 Previous Clinical Trials
97,273 Total Patients Enrolled
NorthShore University HealthSystemLead Sponsor
132 Previous Clinical Trials
737,841 Total Patients Enrolled
Stuart M Sprague, DOPrincipal InvestigatorNorthShore University HealthSystem

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Mar 2025